产品说明
应用
Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.
包装
10, 50 mg in glass bottle
生化/生理作用
Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.
Broad-spectrum anticonvulsant.
特点和优势
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
诊断含义
Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.
基本信息
| 经验(实验)分子式 | C10H8F2N4O |
| 分子量 | 238.19 |
| MDL编号 | MFCD00865314 |
| PubChem化学物质编号 | 24724595 |
| NACRES | NA.77 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| 颜色 | white |
| 溶解性 | DMSO: 9 mg/mL |
| 创始人 | Novartis |
| 储存温度 | −20℃ |
| SMILES string | NC(=O)c1cn(Cc2c(F)cccc2F)nn1 |
| InChI | 1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17) |
| InChI key | POGQSBRIGCQNEG-UHFFFAOYSA-N |
| Gene Information | human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335) |
安全信息
| 象形图 |   |
| 警示用语： | Warning |
| 危险声明 | H336 - H351 - H361fd |
| 预防措施声明 | P201 - P202 - P261 - P271 - P280 - P308 + P313 |
| 危险分类 | Carc. 2 - Repr. 2 - STOT SE 3 |
| 靶器官 | Central nervous system |
| 储存分类代码 | 11 - Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
m.cnreagent.com
